Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
TGP5KVLFbsuCSnBE
